Log in

NASDAQ:STIM - Neuronetics Stock Price, Forecast & News

+0.04 (+0.92 %)
(As of 01/19/2020 04:00 PM ET)
Today's Range
Now: $4.39
50-Day Range
MA: $4.42
52-Week Range
Now: $4.39
Volume164,222 shs
Average Volume117,754 shs
Market Capitalization$81.79 million
P/E RatioN/A
Dividend YieldN/A
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:STIM



Sales & Book Value

Annual Sales$52.78 million
Book Value$4.04 per share


Net Income$-24,100,000.00


Market Cap$81.79 million
Next Earnings Date3/3/2020 (Estimated)
OptionableNot Optionable

Receive STIM News and Ratings via Email

Sign-up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.

Neuronetics (NASDAQ:STIM) Frequently Asked Questions

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

How were Neuronetics' earnings last quarter?

Neuronetics Inc (NASDAQ:STIM) announced its earnings results on Tuesday, November, 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.04. The business earned $16 million during the quarter, compared to analyst estimates of $16.13 million. Neuronetics had a negative return on equity of 44.10% and a negative net margin of 45.35%. View Neuronetics' Earnings History.

When is Neuronetics' next earnings date?

Neuronetics is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Neuronetics.

What price target have analysts set for STIM?

2 Wall Street analysts have issued 1-year target prices for Neuronetics' shares. Their forecasts range from $11.00 to $28.00. On average, they anticipate Neuronetics' stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 344.2% from the stock's current price. View Analyst Price Targets for Neuronetics.

What is the consensus analysts' recommendation for Neuronetics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neuronetics.

What are Wall Street analysts saying about Neuronetics stock?

Here are some recent quotes from research analysts about Neuronetics stock:
  • 1. According to Zacks Investment Research, "Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), is the transcranial magnetic stimulation treatment for depressive disorder. Neuronetics, Inc. is based in Malvern, United States. " (11/9/2019)
  • 2. BTIG Research analysts commented, "$25 PT Neuronetics reported 4Q18 results with both capital sales and treatment revenue surpassing our forecast. Ending BDM count was in-line with expectations, implying rep productivity is ahead of planned (mgmt confirmed the same). Looking ahead to FY19, top-line guidance brackets current Street estimates. Mgmt is assuming more rep hires than the Street, driving up the operating expense outlook. On underlying assumptions, mgmt appears to be basing forecasts on historical productivity metrics instead of more recent encouraging trends likely creating upside. Additionally, the company does not appear to be aggressively signaling gross margin expansion though we still feel a greater mix of higher-margin consumable sales should push this metric higher." (3/6/2019)

Has Neuronetics been receiving favorable news coverage?

Headlines about STIM stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Neuronetics earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Neuronetics.

Are investors shorting Neuronetics?

Neuronetics saw a decline in short interest in December. As of December 31st, there was short interest totalling 246,900 shares, a decline of 11.1% from the December 15th total of 277,700 shares. Based on an average daily volume of 146,400 shares, the short-interest ratio is currently 1.7 days. Approximately 2.9% of the shares of the company are short sold. View Neuronetics' Current Options Chain.

Who are some of Neuronetics' key competitors?

What other stocks do shareholders of Neuronetics own?

Who are Neuronetics' key executives?

Neuronetics' management team includes the folowing people:
  • Mr. Christopher A. Thatcher, CEO, Pres & Director (Age 54)
  • Mr. Peter L. Donato, CFO, VP & Corp. Sec. (Age 49)
  • Mr. Gregory Harper, VP of R&D, Operations and Product Devel. (Age 58)
  • Ms. Cassie Hallberg, VP of Marketing
  • Mr. Daniel Guthrie, Chief Commercial Officer & VP (Age 42)

When did Neuronetics IPO?

(STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Who are Neuronetics' major shareholders?

Neuronetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.40%). Company insiders that own Neuronetics stock include Brian E Farley, Christopher Thatcher, Daniel Guthrie, Gregory Harper, Peter Donato, Stephen Furlong, Stephen M Campe and Wilfred E Jaeger. View Institutional Ownership Trends for Neuronetics.

Which major investors are buying Neuronetics stock?

STIM stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Neuronetics stock in the last two years include Brian E Farley, Daniel Guthrie, Gregory Harper, Stephen Furlong, Stephen M Campe and Wilfred E Jaeger. View Insider Buying and Selling for Neuronetics.

How do I buy shares of Neuronetics?

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $4.39.

How big of a company is Neuronetics?

Neuronetics has a market capitalization of $81.79 million and generates $52.78 million in revenue each year. The company earns $-24,100,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Neuronetics employs 191 workers across the globe.View Additional Information About Neuronetics.

What is Neuronetics' official website?

The official website for Neuronetics is http://www.neurostar.com/.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]

MarketBeat Community Rating for Neuronetics (NASDAQ STIM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  159
MarketBeat's community ratings are surveys of what our community members think about Neuronetics and other stocks. Vote "Outperform" if you believe STIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Featured Article: S&P/ASX 200 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel